Why the study?
Does the CETP polymorphism (TaqIB) B2 allele increase the risk of recurrent events in postinfarction patients with high HDL-C and high CRP levels compared to B1 homozygotes?
Does the CETP polymorphism (TaqIB) B2 allele increase the risk of recurrent events in postinfarction patients with high HDL-C and high CRP levels compared to B1 homozygotes?
Postinfarction patients with high HDL-C and CRP levels who carry the CETP TaqIB B2 allele are at increased risk for recurrent events, suggesting impaired HDL remodeling.
Should not yet change post-MI risk stratification; hypothesis-generating for CETP TaqIB B2 effects in high HDL-C/CRP subgroups.
OBJECTIVE: To investigate the roles of inflammation and a cholesteryl ester transfer protein (CETP) polymorphism potentially related to recent findings demonstrating coronary risk with increasing high-density lipoprotein cholesterol (HDL-C) level. METHODS AND RESULTS: A novel graphical exploratory data analysis tool allowed the examination of coronary risk in postinfarction patients relating to HDL-C and C-reactive protein levels. Results demonstrated a high-risk subgroup, defined by high HDL-C and C-reactive protein levels, exhibiting larger HDL particles and lower lipoprotein-associated phospholipaseA(2) levels than lower-risk patients. Subgroup CETP-associated risk was probed using a functional CETP polymorphism (TaqIB, rs708272). In the high-risk subgroup, multivariable modeling revealed greater risk for B2 allele carriers (less CETP activity) versus B1 homozygotes (hazard ratio, 2.41; 95% CI, 1.04 to 5.60; P=0.04). Within the high-risk subgroup, B2 allele carriers had higher serum amyloid A levels than B1 homozygotes. Evidence also demonstrates that CETP genotypic differences in HDL subfraction distributions regarding non-HDL-C and lipoprotein-associated phospholipaseA(2) may potentially relate to impaired HDL remodeling. CONCLUSIONS: Postinfarction patients with high HDL-C and C-reactive protein levels demonstrate increased risk for recurrent events. Future studies should aim at characterizing altered HDL particles from such patients and at elucidating the mechanistic details related to inflammation and HDL particle remodeling. Such patients should be considered in drug trials involving an increase in HDL-C level.
No takes yet. Share an insight, caveat, or question.
Corsetti et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: